Stereotactic Body Radiation Therapy(SBRT) in liver tumors -Dosimetric and clinical Outcomes

Tata Memorial Hospital0 个研究点目标入组 0 人开始时间: 待定最近更新: 2022年8月2日

试验速览

暂无简介。

•Histologically or Radiologically proven primary or metastatic liver tumor
•-Unresectable or Unablatable RFA tumor not amenable to TACE or patient unwilling for it.
•-Karnofsky Performance Scale KPS equal or greater than 60
•-Inclusion criteria for patient may include any of following
•-Unresectable tumor with Main portal vein thrombus and or tumor invasion into hepatic vein or IVC
•-Tumor diameter up to 15cm or Less than 5 liver metastases or Multifocal disease including bilobar more than with spared liver vol 700 cc
•-For metastases the primary tumor site has been adequately treated if metachronous disease and disease-free interval DFI is more than 12 months.
•-Patients who received prior any Liver Directed Therapy presented with recurrent or residual tumor
•-Extrahepatic disease which can be included in SBRT volume

•-Impossibility to participate at the study procedures due to geographic and social or psychological reasons.
•-BCLC D and Child Pugh class C and B8-9
•-Pregnancy and women under lactation
•-Patient not consenting for the prospective cohort.
•-Tumor suitable for ablation that will include
•-Single lesion less than or equal to 5 cm and deemed suitable for RFA.
•-For HCC upto 3 lesion less than 3 cm and deemed suitable for RFA.
•-For metastases upto 5 lesion less than 3 cm and deemed suitable for RFA.

发起方